JP2007262090A5 - - Google Patents

Download PDF

Info

Publication number
JP2007262090A5
JP2007262090A5 JP2007180835A JP2007180835A JP2007262090A5 JP 2007262090 A5 JP2007262090 A5 JP 2007262090A5 JP 2007180835 A JP2007180835 A JP 2007180835A JP 2007180835 A JP2007180835 A JP 2007180835A JP 2007262090 A5 JP2007262090 A5 JP 2007262090A5
Authority
JP
Japan
Prior art keywords
composition
factor
polysorbate
subcutaneously
intravenously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007180835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007262090A (ja
JP4879104B2 (ja
Filing date
Publication date
Priority claimed from US08/591,332 external-priority patent/US5770700A/en
Application filed filed Critical
Publication of JP2007262090A publication Critical patent/JP2007262090A/ja
Publication of JP2007262090A5 publication Critical patent/JP2007262090A5/ja
Application granted granted Critical
Publication of JP4879104B2 publication Critical patent/JP4879104B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007180835A 1996-01-25 2007-07-10 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 Expired - Lifetime JP4879104B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/591,332 1996-01-25
US08/591,332 US5770700A (en) 1996-01-25 1996-01-25 Liquid factor IX formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP9526917A Division JP2000504327A (ja) 1996-01-25 1997-01-09 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方

Publications (3)

Publication Number Publication Date
JP2007262090A JP2007262090A (ja) 2007-10-11
JP2007262090A5 true JP2007262090A5 (enExample) 2010-01-14
JP4879104B2 JP4879104B2 (ja) 2012-02-22

Family

ID=24366077

Family Applications (4)

Application Number Title Priority Date Filing Date
JP9526917A Withdrawn JP2000504327A (ja) 1996-01-25 1997-01-09 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方
JP2006141684A Pending JP2006257099A (ja) 1996-01-25 2006-05-22 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2007180835A Expired - Lifetime JP4879104B2 (ja) 1996-01-25 2007-07-10 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2010106673A Withdrawn JP2010189433A (ja) 1996-01-25 2010-05-06 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP9526917A Withdrawn JP2000504327A (ja) 1996-01-25 1997-01-09 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方
JP2006141684A Pending JP2006257099A (ja) 1996-01-25 2006-05-22 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010106673A Withdrawn JP2010189433A (ja) 1996-01-25 2010-05-06 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Country Status (8)

Country Link
US (1) US5770700A (enExample)
EP (1) EP0876155B1 (enExample)
JP (4) JP2000504327A (enExample)
AT (1) ATE270557T1 (enExample)
AU (1) AU726498B2 (enExample)
CA (1) CA2241319A1 (enExample)
DE (1) DE69729786T2 (enExample)
WO (1) WO1997026909A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP2039368A3 (en) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
PL370656A1 (en) * 2001-12-21 2005-05-30 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP2311437A1 (en) * 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
WO2005094873A1 (en) * 2004-03-19 2005-10-13 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
DE602006018622D1 (de) * 2005-06-30 2011-01-13 Ge Healthcare Bio Sciences Nachweisverfahren für die genexpression
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8449520B2 (en) * 2007-03-19 2013-05-28 HemCon Medical Technologies Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2150264A4 (en) 2007-04-26 2014-09-24 Bayer Healthcare Llc STABILIZATION OF LIQUID SOLUTIONS OF A RECOMBINANT PROTEIN FOR FROZEN STORAGE
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5599778B2 (ja) * 2008-04-14 2014-10-01 デピュイ・シンセス・プロダクツ・エルエルシー 液体緩衝ｇｄｆ−５製剤
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
EP2538967A1 (en) * 2010-02-24 2013-01-02 Arecor Limited Stable compositions of factor ix
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EP2972230B1 (en) * 2013-03-15 2021-07-21 Hycor Biomedical LLC Device and associated method for performing luminescence and fluorescence measurements of a sample
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
WO2019074886A1 (en) 2017-10-09 2019-04-18 Terumo Bct Biotechnologies, Llc LYOPHILIZATION CONTAINER AND METHOD OF USE
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
IT1171737B (it) * 1983-10-10 1987-06-10 Vamatex Spa Gancio per la guida di nastri portapinze all'interno del passo di telai di tessitura e complesso di guida con esso realizzabile
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4952675A (en) * 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
WO1986006408A1 (en) * 1985-04-22 1986-11-06 Genetics Institute, Inc. HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
ES2045167T5 (es) * 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
DE3828009A1 (de) * 1988-08-18 1990-02-22 Wolfgang D Zapp Rahmen aus strangprofilen
JP2715104B2 (ja) * 1988-08-18 1998-02-18 株式会社ミドリ十字 トロンビン乾燥製剤
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
JP2722143B2 (ja) * 1991-09-03 1998-03-04 株式会社ミドリ十字 トリプシンインヒビター含有凍結乾燥製剤
JPH05331071A (ja) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
ATE249234T1 (de) * 1993-12-17 2003-09-15 Mochida Pharm Co Ltd Lösliches thrombomodulin enthaltende zubereitung
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations

Similar Documents

Publication Publication Date Title
JP2010530846A5 (enExample)
JP2012515184A5 (enExample)
JP2007527914A5 (enExample)
JP2010285439A5 (enExample)
JP2005518433A5 (enExample)
MX2010005676A (es) Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
WO2009134057A3 (ko) 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
JP2014518860A5 (enExample)
JP2012502909A5 (enExample)
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
JP2009541409A5 (enExample)
JP2009537554A5 (enExample)
JP2013541583A5 (enExample)
HRP20151091T1 (hr) UPORABA 24-norUDCA
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
JP2007119497A5 (enExample)
WO2011055383A3 (en) Intranasal delivery to improve the performance of children suffering from dyslexia
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
JP2009516719A5 (enExample)
WO2009019307A3 (en) Oral calcitonin compositions and applications thereof
JP2008539169A5 (enExample)
JP2011012060A5 (enExample)
JP2010523660A5 (enExample)